| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $422.9M | — | -25.9% |
| Cost of Revenue | $159.8M | — | -22.2% |
| R&D Expense | $39.7M | — | -20.9% |
| SG&A Expense | $104.1M | — | +65.7% |
| Operating Income | -$40.1M | — | -212.0% |
| Pre-tax Income | -$17.8M | — | +94.2% |
| Income Tax | -$15.6M | — | +80.3% |
| Net Income | -$71.9M | — | +66.8% |
| EPS (Basic) | -$0.94 | — | +64.4% |
| EPS (Diluted) | -$0.94 | — | +64.4% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $1.11B | +15.9% | -4.0% |
| Accounts Receivable | $328.8M | -26.7% | -16.1% |
| Current Assets | $1.55B | +0.4% | -8.5% |
| Total Assets | $6.82B | -4.4% | -5.1% |
| Current Liabilities | $419.8M | -25.2% | -33.1% |
| Long-term Debt | $1.40B |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Capital Expenditures | $8.0M | — | +71.0% |
| -1.7% |
| Stockholders' Equity | $4.55B | -3.9% | -3.5% |